Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer
Conditions
Keywords
T cell activation, immunotherapy, ovarian, fallopian tube, peritoneal, cancer, recurrent, tumor, measurable
Brief summary
T cell activating therapy DPX-Survivac, low dose oral cyclophosphamide, and IDO1 inhibitor epacadostat will be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential immune-modulating activity of the combination of these agents.
Detailed description
The Phase 1b component is a multicenter, non-randomized, open label, uncontrolled, safety and effectiveness study to identify the recommended Phase 2 dose (R2PD) of epacadostat in combination with DPX-Survivac and cyclophosphamide. The Phase 2 component was initially a multicenter, randomized, open-label study to evaluate the safety and effectiveness of DPX-Survivac + cyclophosphamide with or without the RP2D of epacadostat. The design of the study has been amended to a single arm study in which up to 16 evaluable subjects will be enrolled to received DPX-Survivac plus intermittent low dose cyclophosphamide (i.e. treatment arm 2).
Interventions
Sponsors
Incyte Corporation
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Histologically confirmed, stage IIc-IV epithelial ovarian, fallopian tube or peritoneal cancer * Platinum-resistant or -sensitive subjects after completing first-line treatment (debulking surgery and adjuvant or neoadjuvant treatment with standard of care treatment such as carboplatin and paclitaxel). Subjects may have had any number of subsequent lines of chemotherapy. * Must have evidence of progressive disease with either biochemical (i.e. rising CA-125) and/or radiologic progression * Must have measurable disease by RECIST v1.1, a successful pre-treatment tumor biopsy, and be willing to undergo tumor biopsy during treatment * Ambulatory with an ECOG 0-1 * Life expectancy ≥ 6 months * Meet protocol-specified laboratory requirements Key
Exclusion criteria
* Eligible for otherwise curative treatment or undergoing concurrent therapy * Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g. anti-CTLA-4, anti-PD-1, anti-PD-L1, or any other antibody or drug specifically targeting T cell co-stimulation) or an IDO inhibitor * Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma in situ, or controlled bladder cancer * Clinical ascites * Any single lesion greater than or equal to 4 cm (per RECIST v1.1) * Malignant bowel obstruction * History of autoimmune disease requiring treatment within the last two years (except vitiligo or diabetes) * Recent history of thyroiditis * Presence of a serious acute infection or chronic infection * Active central nervous system (CNS) or leptomeningeal metastasis (brain metastases) * GI condition that might limit absorption of oral agents * Other serious intercurrent chronic or acute illness, including myocardial infarction or cerebrovascular event within 6 months * Ongoing treatment with steroid therapy or other immunosuppressive * Receipt of monoamine oxidase inhibitors (MAOIs) or UGT1A9 inhibitors * Receipt of live attenuated vaccines * Acute or chronic skin and/or microvascular disorders * Edema or lymphedema in the lower limbs \> grade 2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety as measured by adverse event reporting (CTCAE) | up to 13 months | — |
| Objective Response Rate (Phase 2 only) | up to 13 months | Evaluated using modified RECIST v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cell mediated immunity as measured by the antigen specific response in peripheral blood | bimonthly for up to 13 months | — |
| Evaluation of treatment-induced changes in tumor infiltrating lymphocytes | at 8 to 10 weeks | — |
| Objective Response Rate (for each treatment group) | up to 13 months | Evaluated using modified RECIST v1.1 |
| Overall Survival | up to 13 months | — |
| Time to Progression | up to 13 months | — |
| Duration of Response | up to 13 months | — |
Countries
Canada, United States
Outcome results
None listed